Tweet
MMWR Morb Mortal Wkly Rep
. 2025 Feb 27;74(6):73-82.
doi: 10.15585/mmwr.mm7406a1. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
Ruth Link-Gelles, Sean Chickery, Alexander Webber, Toan C Ong, Elizabeth A K Rowley, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Michelle A Barron, Sarah E Reese, Charlene McEvoy, Tamara Sheffield, Allison L Naleway, Ousseny Zerbo, Colin Rogerson, Wesley H Self, Yuwei Zhu, Adam S Lauring, Emily T Martin, Ithan D Peltan, Adit A Ginde, Nicholas M Mohr, Kevin W Gibbs, David N Hager, Matthew E Prekker, Amira Mohamed, Nicholas Johnson, Jay S Steingrub, Akram Khan, Jamie R Felzer, Abhijit Duggal, Jennifer G Wilson, Nida Qadir, Christopher Mallow, Jennie H Kwon, Cristie Columbus, Ivana A Vaughn, Basmah Safdar, Jarrod M Mosier, Estelle S Harris, James D Chappell, Natasha Halasa, Cassandra Johnson, Karthik Natarajan, Nathaniel M Lewis, Sascha Ellington, Emily L Reeves, Jennifer DeCuir, Meredith McMorrow, Clinton R Paden, Amanda B Payne, Fatimah S Dawood, Diya Surie; CDC COVID-19 Vaccine Effectiveness Collaborators
Collaborators, Affiliations
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
. 2025 Feb 27;74(6):73-82.
doi: 10.15585/mmwr.mm7406a1. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
Ruth Link-Gelles, Sean Chickery, Alexander Webber, Toan C Ong, Elizabeth A K Rowley, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Michelle A Barron, Sarah E Reese, Charlene McEvoy, Tamara Sheffield, Allison L Naleway, Ousseny Zerbo, Colin Rogerson, Wesley H Self, Yuwei Zhu, Adam S Lauring, Emily T Martin, Ithan D Peltan, Adit A Ginde, Nicholas M Mohr, Kevin W Gibbs, David N Hager, Matthew E Prekker, Amira Mohamed, Nicholas Johnson, Jay S Steingrub, Akram Khan, Jamie R Felzer, Abhijit Duggal, Jennifer G Wilson, Nida Qadir, Christopher Mallow, Jennie H Kwon, Cristie Columbus, Ivana A Vaughn, Basmah Safdar, Jarrod M Mosier, Estelle S Harris, James D Chappell, Natasha Halasa, Cassandra Johnson, Karthik Natarajan, Nathaniel M Lewis, Sascha Ellington, Emily L Reeves, Jennifer DeCuir, Meredith McMorrow, Clinton R Paden, Amanda B Payne, Fatimah S Dawood, Diya Surie; CDC COVID-19 Vaccine Effectiveness Collaborators
Collaborators, Affiliations
- PMID: 40014628
- DOI: 10.15585/mmwr.mm7406a1
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.